Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
Abstract BRAF mutant metastatic colorectal cancer has long been considered a tumor with a poor prognosis and a poor response to chemotherapy. Despite the efficacy of targeted therapy with multi-targeted blockade of the mitogen-activated protein kinase (MAPK) signaling pathway has brought a glimmer o...
Main Authors: | Jie Zhong, Zijian Sun, Sheng Li, Liu Yang, Yuepeng Cao, Jun Bao |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2023-06-01
|
Series: | Discover Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s12672-023-00718-y |
Similar Items
-
The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
by: Angela Djanani, et al.
Published: (2020-11-01) -
BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
by: Junjia Liu, et al.
Published: (2023-09-01) -
The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Maximilian Haist, et al.
Published: (2022-04-01) -
Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <i>BRAF</i>V600 Melanoma: Current Status and Future Perspectives
by: Michèle Welti, et al.
Published: (2022-11-01) -
PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)